Combating chemoresistance: Current approaches & nanocarrier mediated targeted delivery
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025
DOI: 10.1016/j.bbcan.2025.189261 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Siuli Shaw und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, Antineoplastic Agents, Drug Delivery Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 160 Literaturangaben. Gefördert von: Shiv Nadar Foundation, Toyota Motor Europe, Amity University.
Abstract (Originalsprache)
Chemoresistance, a significant challenge in effective cancer treatment needs clear elucidation of the underlying molecular mechanism for the development of novel therapeutic strategies. Alterations in transporter pumps, oncogenes, tumour suppressor genes, mitochondrial function, DNA repair processes, autophagy, epithelial-mesenchymal transition (EMT), cancer stemness, epigenetic modifications, and exosome secretion lead to chemoresistance. Despite notable advancements in targeted cancer therapies employing both small molecules and macromolecules success rates remain suboptimal due to adverse effects like drug efflux, target mutation, increased mortality of normal cells, defective apoptosis, etc. This review proposes an advanced nanotechnological technique precisely targeting molecular determinants of chemoresistance which holds promise for enhancing cancer treatment efficacy. Further, the review explores various cancer hallmarks and pathways implicated in chemoresistance, current therapeutic modalities, and their limitations. It advocates the combination of nanoparticle-conjugated conventional drugs and natural compounds to specifically target molecular pathways that can potentially reverse or minimize chemoresistance incidences in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
- Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida, Uttar Pradesh, India.
- School of Materials Science and Engineering, The University of New South Wales, Sydney, NSW 2052, Australia.
- Amity Institute of Nanotechnology, Amity University, Noida, Uttar Pradesh, India. Electronic address: rnayak@amity.edu.
- Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India; Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida, Uttar Pradesh, In…
Förderung
- Shiv Nadar Foundation
- Toyota Motor Europe
- Amity University
- Bundesministerium des Innern, für Bau und Heimat
Zitieren
APA
Shaw, S., Pore, S. K., Liu, D., Kumeria, T., Nayak, R., & Bose, S. (2025). Combating chemoresistance: Current approaches & nanocarrier mediated targeted delivery. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189261
Vancouver
Shaw S, Pore SK, Liu D, Kumeria T, Nayak R, Bose S. Combating chemoresistance: Current approaches & nanocarrier mediated targeted delivery. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189261
BibTeX
@article{Shaw2025,
author = {Shaw, Siuli and Pore, Subrata Kumar and Liu, Dutong and Kumeria, Tushar and Nayak, Ranu and Bose, Sudeep},
title = {Combating chemoresistance: Current approaches & nanocarrier mediated targeted delivery},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
doi = {10.1016/j.bbcan.2025.189261}
}
EUVIMED